LINC01244: A Potential Drug Target for Cancer (G103021164)

Target Name: CASC21

NCBI ID: G103021164

CASC21

Other Name(s): LINC01244 | CARLO2 | cancer susceptibility 21 | CARLo-2 | Cancer susceptibility 21

LINC01244: A Potential Drug Target for Cancer

Cancer-associated neoblasts (CASC) are cells that are present in the tumor microenvironment and have been shown to contribute to cancer progression. These cells are able to evade the host immune system and have been shown to promote tumor growth and metastasis. While there are many potential drug targets and biomarkers that have been identified in theCASC, the focus of this article will be on one of them: LINC01244.

LINC01244 is a protein that is expressed in various tissues, including the brain, heart, and blood vessels. It is a member of the LINC (long non-coding RNA) family, which is known for its role in regulating gene expression and cell function . LINC01244 has been shown to play a role in several important cellular processes, including cell adhesion, migration, and invasion.

One of the key functions of LINC01244 is its role in cell adhesion. Adhesion is the process by which cells stick together and form tissues. LINC01244 is known to be involved in the formation of tight junctions, which are between cells that are involved in cell signaling and signaling pathways. These tight junctions are important for maintaining tissue structure and function, and are often targeted by drugs that are used to treat diseases such as cancer.

Another function of LINC01244 is its role in cell migration. Migration is the process by which cells move from one location to another in the body. LINC01244 is known to be involved in the formation of mitotic spindles, which are the structures that are used by cells to pull their chromosomes together during the cell division process. These spindles are important for ensuring that the chromosomes are divided evenly between the two new cells that are formed.

In addition to its role in cell adhesion and migration, LINC01244 has also been shown to be involved in the process of invasion. Invasion is the process by which cells break away from their surrounding tissue and migrate towards a new location. LINC01244 is known to be involved in the formation of the matrix, which is the structure that is used by cells to support their growth and invasion.

The role of LINC01244 in cancer progression is still being studied, but it is clear that it plays an important role. LINC01244 has been shown to be expressed in a variety of cancer types, including breast, ovarian, and colorectal cancers. It has also been shown to be involved in the development of cancer stem cells, which are cells that are able to self-replify and promote tumor growth.

One of the challenges in studying the role of LINC01244 in cancer is its complex structure. LINC01244 is a protein that is expressed in many different tissues, making it difficult to study its effects in a specific context. Additionally, the functions of LINC01244 are not yet fully understood, which can make it difficult to predict how it will be effective in treating cancer.

Despite these challenges, researchers are continuing to study the role of LINC01244 in cancer. One of the most promising strategies for studying its effects is to use drugs that target its functions. For example, researchers have shown that inhibiting the activity of LINC01244 using small molecules can inhibit the growth and migration of cancer cells.

Another approach that is being explored is using RNA-based therapies to target LINC01244. RNA-based therapies are a type of therapy that use small interfering RNA (siRNA) to

Protein Name: Cancer Susceptibility 21

The "CASC21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CASC21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets